Amneal Pharmaceuticals (NASDAQ:AMRX) Lowered to “Hold” Rating by Zacks Research

Zacks Research cut shares of Amneal Pharmaceuticals (NASDAQ:AMRX) from a strong-buy rating to a hold rating in a research report report published on Monday morning,Zacks.com reports.

AMRX has been the topic of several other research reports. Truist Financial lifted their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Barclays initiated coverage on shares of Amneal Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $15.00 target price on the stock. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Amneal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.20.

Amneal Pharmaceuticals Stock Performance

Shares of Amneal Pharmaceuticals stock traded up $0.30 during mid-day trading on Monday, hitting $12.62. 109,434 shares of the stock were exchanged, compared to its average volume of 2,521,501. Amneal Pharmaceuticals has a 12 month low of $6.68 and a 12 month high of $15.42. The company has a 50-day simple moving average of $13.42 and a 200 day simple moving average of $12.32. The company has a market capitalization of $3.97 billion, a P/E ratio of 54.87 and a beta of 1.32.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Kemnay Advisory Services Inc. purchased a new position in Amneal Pharmaceuticals in the 4th quarter valued at approximately $26,000. Federated Hermes Inc. increased its holdings in shares of Amneal Pharmaceuticals by 1,680.6% in the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares during the period. Spire Wealth Management increased its holdings in shares of Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares during the period. Transamerica Financial Advisors LLC increased its holdings in shares of Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after purchasing an additional 2,460 shares during the period. Finally, Comerica Bank increased its holdings in shares of Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares during the period. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.